This Viewpoint examines how clinicians should approach FDA-approved amyloid-targeting therapies (lecanemab and donanemab) in Alzheimer disease patients who also have suspected non-AD copathologies, focusing on individualized decision-making and current evidence gaps.
No primary quantitative results are reported; the authors highlight that evidence for ATT use in patients with AD copathologies remains limited, and that clinical judgment and shared decision-making are currently required while prospective studies are awaited.
As a Viewpoint, this article presents expert opinion rather than original data, with no systematic review or empirical analysis to support specific recommendations.
When considering lecanemab or donanemab for patients with early symptomatic AD and suspected copathologies (e.g., other neurodegenerative conditions), clinicians should apply individualized clinical judgment and engage patients in shared decision-making given the current lack of evidence in this population.
Explore related topics
